← All trials
NCT05015608
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 22, 2021
- Primary completion
- Sep 15, 2024
- Completion date
- Nov 30, 2024
- First posted
- Aug 20, 2021
- Last posted
- Nov 30, 2021
- Enrollment
- 250
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hutchison MediPharmaLead sponsor
- Chinese Academy of Medical SciencesOverall official - principal investigator
- Jiao Tong UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.